The buying action over the last few months coupled with the past history of the stock definitely signal a buy. Very little selling in this range combined with past spikes in buying that led to the stock reaching the .20s and .40s in recent years is what makes this an attractive buy at this price.
Add that with the reported success of the previous melanoma trial, the complete response of one of the patients of the previous Phase I ovarian cancer trial, the FDA's approval of dendreon's provenge using a very similar treatment, and NWBO's seeming success with it's brain cancer treatment.
It all adds up to a buy.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM